Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
FDA chief blames decades of regulatory failure for misleading pharma ads
The US Food and Drug Administration (FDA) commissioner Martin Makary has described the current state of direct-to-consumer pharmaceutical advertising as…
-
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising…
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
-
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The…
-
UK pharma industry risks losing world-leading status as investment plummets
The UK is at risk of losing its world-leading life sciences status due to investment being captured elsewhere on the…
-
Trump tasks FDA to crack down on misleading drug advertising
US President Donald Trump is launching an enforcement drive against pharmaceutical companies and social media influencers who are responsible for…
-
Novo Nordisk slashes 11% of workforce as Eli Lilly pressure tightens
Novo Nordisk will cut 9,000 jobs as part of a savings plan as the drugmaker fails to grapple with the…
-
US Government signs $56m smallpox/mpox vaccine order despite political disarray
The US Government has ordered $56m worth of mpox/smallpox vaccines to bolster public health preparedness, despite wider uncertainty in the…
-
Novo’s Ozempic price cut expected to slow market share erosion
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients…